PMV Pharmaceuticals reported Phase I data for rezatapopt, a small molecule designed to reactivate mutant p53 in tumors carrying the TP53 Y220C mutation. Published in the New England Journal of Medicine, the study showed objective responses across multiple heavily pretreated solid tumors and established a recommended Phase II dose with an acceptable safety profile. Authors and PMV highlight biomarker‑linked activity consistent with selective binding to the Y220C pocket and restoration of wild‑type p53 function. The company plans registrational strategies in platinum‑resistant ovarian cancer and expects to use these data to support regulatory filings.